The drug and medical device maker Johnson & Johnson kicked off the healthcare earnings season with a better-than-anticipated report early Wednesday, as sales and earnings came in above expectations.That’s a good sign for the healthcare sector,

Illinois Comptroller Susana Mendoza said Wednesday she’ll give up her statewide office as she considers her “next biggest challenge” — which sure sounds like a potential b

Wis., discusses mortgage fraud accusations against Democratic Sen. Adam Schiff, Senate efforts to codify DOGE spending cuts, and his investigation into former President Biden's pardons.

Johnson & Johnson raised its full-year sales forecast on Wednesday after beating estimates for second-quarter profit on strong demand for its cancer drug, Darzalex, and strength in its medical device business.

Johnson shared yet another personal insight that nobody asked for: His jizz has substantially more microplastics in it than his blood does. On X on Tuesday, Johnson posted: “I have microplastics in my ejaculate.

Johnson & Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, beating the consensus of $2.68. The pharmaceutical giant reported sales of $23.

In the second quarter, J&J’s worldwide oncology sales shot up more than 20 per cent, offsetting declines in sales of its popular immune system medicine Stelara, which is facing a patent cliff. Sales in its smaller, medtech division increased 6 per cent.

The third-term Democrat from Dallas faces long odds in a state that has only elected Republicans to statewide office for three decades.